LETYBO®

About LETYBO® — Hugel’s FDA-Approved Botulinum Toxin Type A

Hugel Inc., a South Korean pharmaceutical company, has focused its portfolio on aesthetic and therapeutic botulinum toxin type A products for more than two decades. Manufacturing takes place at Hugel’s facility in Chuncheon, and the active ingredient — letibotulinumtoxinA-wlbg — is a highly purified botulinum toxin type A. Once injected, it temporarily interrupts acetylcholine signaling at the neuromuscular junction, reducing contraction in the targeted muscle group. That mechanism places the LETYBO® neurotoxin within the broader class of injectable neuromodulators used in modern aesthetic practice.

The commercial presentation most frequently referenced in trial protocols is the LETYBO® 50UI vial, a 50-Unit single-dose lyophilized powder that requires reconstitution with sterile saline. A 100-Unit vial is also covered under the US label. Both must be handled under cold-chain conditions and are intended for professional intramuscular injection, not self-administration.

LETYBO® vs BOTULAX® — The Critical Distinction

Both Korean botox products are manufactured by Hugel Inc. at the same facility, come from the same CBFC26 production strain, and carry the same International Nonproprietary Name, letibotulinumtoxinA. What separates them is not the molecule but the label and the regulatory dossier attached to it.

BOTULAX® is Hugel’s international export trade name used in South Korea (MFDS-approved) and in several other jurisdictions worldwide. It does not hold a valid European marketing authorization. LETYBO® is the trade name under which the same molecule was registered with the US FDA and, separately, with European regulators through the Decentralised Procedure in partnership with Croma-Pharma. This is why a US-licensed practitioner can prescribe LETYBO® for glabellar lines, while BOTULAX® is not authorized for aesthetic use in the United States or in the EU/UK.

FDA Approval and Regulatory Status

LETYBO® FDA approval was granted in early 2024 for the temporary improvement of moderate to severe glabellar lines in adults, making it the first letibotulinumtoxinA product to reach that regulatory milestone in the US market [1][3]. The Biologics License Application was validated in extensive clinical trials, including a Phase III program that enrolled more than one thousand adult participants, and the responder-rate data supported the FDA’s efficacy and safety threshold for the glabellar indication [1][3].

Beyond the United States, LETYBO® holds regulatory status across several major markets:

• National marketing authorizations across EU member states and the UK, secured through the Decentralised Procedure with Croma-Pharma as marketing authorization holder
• MFDS approval in South Korea
• Additional authorizations in selected Asia-Pacific and Latin American markets
• Prescription-only classification in every jurisdiction where it is approved

The precise labeled indication and permitted upper-face uses can vary by region, and clinics importing product for multi-market practices should always cross-reference the destination-market SmPC or IFU rather than assume the US label applies globally.

Dosage, Onset, Duration, and Storage

The approved LETYBO® dose for glabellar lines is 20 Units per treatment session, delivered across five intramuscular injection sites in the corrugator and procerus complex, with 4 Units in 0.1 mL per site [4]. Each vial is reconstituted with preservative-free 0.9% sodium chloride: 1.25 mL for the 50-Unit vial and 2.5 mL for the 100-Unit vial, producing the same 4 Units per 0.1 mL working concentration [4].

Onset for LETYBO® injections falls within the hours-to-weeks window characteristic of the botulinum toxin type A class, though most patients start to see softening between day three and day seven. Peak effect typically settles by day ten to fourteen. Practitioners should communicate onset as a window rather than a fixed day count.

For the glabellar indication, duration generally runs three to four months. When 20 Units of the CBFC26-strain toxin, now marketed as LETYBO®, was compared head-to-head with 20 Units of onabotulinumtoxinA in an earlier South Korean non-inferiority study, response rates and duration were comparable, not superior [2].

Unopened LETYBO® vials should be stored between 2 °C and 8 °C, and freezing is not permitted [4]. Reconstituted product should be refrigerated between uses and discarded within 24 hours of preparation.

LETYBO® Indications and Approved Use

The FDA-reviewed indication is narrow and specific: moderate to severe glabellar lines in adults. The European authorized indication mirrors this position — moderate to severe glabellar lines in adults, and nothing broader. Expanded upper-face labeling for lateral canthal lines (crow’s feet) or horizontal forehead lines in Europe belongs to other botulinum toxins like BOCOUTURE®/XEOMIN® and BOTOX®, not to LETYBO®.

A suitable candidate for LETYBO® generally presents with visible dynamic vertical creases between the brows at maximum frown, has aesthetic goals compatible with temporary neuromodulation, and has no contraindications to botulinum toxin type A treatment. Off-label use in adjacent facial areas occurs at practitioner discretion under existing clinical judgment for the BTX-A class, but any such application sits outside the FDA-reviewed and European-authorized evidence base.

Published LETYBO® before-and-after imagery from the pivotal trials shows visible glabellar softening at rest and at maximum frown. Clinical LETYBO® results in practice depend on injection accuracy, dilution, muscle mass, and prior treatment history, and clinics planning LETYBO® treatments should set patient expectations accordingly.

Full LETYBO® Product Range — Where to Buy LETYBO® Wholesale

The LETYBO® manufacturer supplies a single letibotulinumtoxinA formulation in two vial strengths, each presented as a single-dose lyophilized powder for professional reconstitution. Clinics considering how to buy LETYBO® wholesale should verify current listed presentations against the destination-market authorization before placing an order, since not every LETYBO® vial size is registered in every jurisdiction.

• LETYBO® 50 Units: the 50-Unit vial (LETYBO® 50UI) most closely aligns with the pivotal glabellar trial protocol and the everyday workflow of single-session upper-face treatment.
• LETYBO® 100 Units: the higher-strength single-dose vial suits practices with greater patient throughput or those planning multiple treatment sessions within the reconstituted product’s 24-hour usable window.

When practitioners evaluate LETYBO® price, or LETYBO® cost across a treatment year, wholesale acquisition of the 100-Unit vial can shift the effective per-unit figure, provided the clinic can consistently use each reconstituted vial within the permitted window without waste. For teams weighing bulk ordering, Doctor Medica’s staff can share verified sourcing information, product documentation, and shipping specifics on request.

LETYBO® Compared to Other BTX-A Products

vs NABOTA® (and Jeuveau®)

NABOTA® (prabotulinumtoxinA) from Daewoong Pharmaceutical is the Korean-manufactured BTX-A closest to LETYBO® in regulatory positioning. It is FDA-approved in the US under the Jeuveau® trade name (Evolus) for moderate to severe glabellar lines, placing both products in the same FDA-approved Korean BTX-A tier. Where they diverge is molecular, with LETYBO® containing letibotulinumtoxinA and NABOTA® containing prabotulinumtoxinA, and by manufacturer. NABOTA®/Jeuveau® has been characterized in US trials as 1:1 with onabotulinumtoxinA, while LETYBO® 20 Units similarly demonstrated equivalence to 20 Units of BOTOX® in the Kim non-inferiority trial [2].

Both require refrigerated storage. Selection between them for US practices tends to hinge on formulary preferences, distributor relationships, and unit economics rather than a demonstrated clinical gap.

vs BOTULAX®

The pair share molecule, strain, and manufacturer, and diverge only on the label and the regulatory dossier attached to each name. Only LETYBO® holds US and European authorizations for aesthetic use. Practitioners cannot import BOTULAX® as an FDA- or EU-compliant substitute for LETYBO® regardless of any price advantage on the international market.

vs BOCOUTURE®

BOCOUTURE® (incobotulinumtoxinA, Merz) is the European trade name for the same “naked” toxin marketed as XEOMIN® in other regions. Its European authorized aesthetic indication covers glabellar lines, crow’s feet, and forehead lines, a broader upper-face footprint than LETYBO® in the same markets. Storage is another practical divider: BOCOUTURE® can be held at room temperature before reconstitution, whereas LETYBO® requires refrigerated storage throughout its shelf life. For European practices where both are available, BOCOUTURE® also benefits from a longer clinical track record.

vs XEOMIN®

For clinics running the LETYBO® vs XEOMIN® comparison at portfolio level, the defining molecular contrast is the absence of complexing proteins in XEOMIN® (incobotulinumtoxinA, Merz, Germany). This “naked toxin” design carries a theoretical lower-immunogenicity argument, though no direct head-to-head trial against LETYBO® has established a clinical difference on that dimension. Both are FDA-approved, and XEOMIN®/BOCOUTURE® also has European marketing authorizations across the region. XEOMIN® has been on the FDA-approved market considerably longer and carries a deeper Western dataset. It also holds a storage advantage, remaining stable at controlled room temperature up to 25 °C before reconstitution. LETYBO® is the newer FDA entrant and brings Korean manufacturing origin into a segment historically led by Western brands.

vs INNOTOX®

INNOTOX® (Medytox) is the odd one out on this shortlist and the only mechanistically distinct comparison. It is the only commercially available liquid, ready-to-inject BTX-A here, eliminating the reconstitution step entirely. LETYBO®, by contrast, is a lyophilized powder that must be reconstituted with sterile saline. INNOTOX® lacks a valid European marketing authorization for aesthetic use and has not received FDA approval, whereas LETYBO® is FDA-approved for glabellar lines and holds European MAs.

LETYBO® Reviews, Safety Profile, and Adverse Events

LETYBO®’s established safety profile is drawn from the pivotal BLESS Phase III program and post-approval surveillance [1][5]. Reported side effects of LETYBO® in clinical studies are consistent with the wider BTX-A class and were largely mild, transient, and self-limiting in the trial population [1]. Practitioner-facing LETYBO® reviews and post-marketing accounts have generally aligned with trial expectations, and Letybo’s effects on glabellar line severity at maximum frown remained clinically meaningful across the studied dosing intervals.

Common LETYBO® side effects reported in the trial dataset and in subsequent LETYBO® reviews include:

• Injection-site bruising and localized tenderness
• Headache, which was the most frequently reported adverse event in the BLESS program
• Mild transient swelling at the injection site
• Eyelid or brow ptosis, typically technique-related rather than product-intrinsic

LETYBO® also carries the FDA boxed warning common to the botulinum toxin type A class regarding potential distant spread of toxin effect. Symptoms can appear hours to weeks after treatment and require prompt clinical assessment when they occur [4]. Contraindications include known hypersensitivity to botulinum toxin components, infection at the proposed injection site, and pre-existing neuromuscular junction disorders that would raise the risk of clinically meaningful weakness [4].

Framed alongside the wider BTX-A category, and in the ongoing LETYBO® vs. BOTOX positioning conversation among practitioners, the trial dataset positions LETYBO® as a credible alternative to BOTOX, supported by robust efficacy and safety data rather than marketing narrative alone [1][2][5].

How Licensed Professionals Buy LETYBO® Online

LETYBO® is a prescription pharmaceutical, and access is restricted to licensed medical professionals sourcing through authorized distribution channels. The checks worth completing before committing to any supplier are consistent across markets:

• Confirm the distributor’s authorization for the destination market and their credentials for BTX-A products specifically
• Verify cold-chain shipping compliance, since temperature excursions during transit can materially compromise product stability
• Request LOT number documentation and certificates of authenticity for the specific batch being supplied
• Cross-check licensing and import requirements applicable to the practitioner’s own jurisdiction

Clinics that need to buy LETYBO® online through a compliant channel can contact Doctor Medica’s staff for verified sourcing information rather than relying on price-led marketplaces. Those planning to buy LETYBO® wholesale for multi-provider practices should pay particular attention to shipping and storage arrangements, since bulk delivery increases the value at risk from any cold-chain break.

Practices reviewing LETYBO® products against alternative Hugel presentations before they commit are welcome to request comparison documentation from our team. When a clinic is preparing to purchase LETYBO® online for the first time, or wants to order LETYBO® online through an authorized supplier, our support staff can walk through documentation requirements and market-specific labeling considerations before any procurement decision is made.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Frequently Asked Questions

What is LETYBO®?

LETYBO® is Hugel Inc.’s FDA-approved letibotulinumtoxinA-wlbg injectable, supplied as a lyophilized powder for reconstitution and indicated for temporary improvement of moderate to severe glabellar lines in adults. It shares its active substance and CBFC26 manufacturing strain with Hugel’s BOTULAX®, which is registered internationally without FDA approval or European marketing authorization.

What is LETYBO® used for?

In the United States and Europe, LETYBO® is authorized solely for the temporary improvement of moderate to severe glabellar lines in adults. Off-label use in other upper-face areas may occur at practitioner discretion but sits outside the authorized evidence base.

Is LETYBO® FDA approved?

Yes. LETYBO® received FDA approval in early 2024 for moderate to severe glabellar lines in adult patients and holds separate national marketing authorizations across EU member states and the UK. It is the first letibotulinumtoxinA product to reach US regulatory approval, which is the defining commercial differentiator within Hugel’s toxin portfolio.

How is LETYBO® different from BOTOX® — and is it better?

The two products come from different manufacturers and carry different active substances: letibotulinumtoxinA (Hugel) for LETYBO® and onabotulinumtoxinA (AbbVie) for BOTOX®. Non-inferiority trial data supported equivalence of 20 Units of LETYBO® with 20 Units of BOTOX® for glabellar lines [2], so on current evidence LETYBO® is comparable to BOTOX® at labeled doses rather than measurably better. Botulinum toxin products are never freely unit-interchangeable and product-specific dosing must always be followed.

How long does LETYBO® take to work?

Softening typically becomes visible between day three and day seven after injection, with peak effect settling around day ten to fourteen. Onset varies with muscle mass, injection placement, dilution, and prior neuromodulator exposure.

How long does LETYBO® last?

Duration for glabellar treatment typically runs three to four months. Trial evidence does not support the view that LETYBO® provides a meaningfully longer duration than BOTOX® at labeled doses.

Does LETYBO® need to be refrigerated?

Yes. Unopened vials must be kept between 2 °C and 8 °C and must not be frozen. Reconstituted product should be refrigerated between uses and discarded 24 hours after preparation to maintain potency and reduce contamination risk.

What are the side effects of LETYBO®?

The Phase III program identified headache as the most common adverse event, alongside injection-site bruising, mild swelling, and localized tenderness. Eyelid or brow ptosis after an upper-face injection is generally technique-related, and the product carries the class-wide FDA boxed warning about the potential distant spread of toxin effects.

Who makes LETYBO®?

Hugel Inc., a South Korean pharmaceutical company based in Chuncheon and focused on aesthetic and therapeutic botulinum toxin products, manufactures LETYBO®. Hugel also produces BOTULAX®, the same letibotulinumtoxinA molecule registered under a different trade name for markets outside the US and EU.

How can practitioners get LETYBO® and find sourcing information?

Licensed practitioners can contact Doctor Medica’s staff for verified supplier information, cold-chain requirements, shipping considerations, and documentation guidance on obtaining LETYBO® through a compliant channel. Availability varies by jurisdiction and destination-market authorization.

Citations and Resources

[1] Mueller, Daniel S et al. “Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.” Aesthetic surgery journal vol. 42,6 (2022): 677-688. doi:10.1093/asj/sjac019

[2] Kim, B J et al. “Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines.” Journal of the European Academy of Dermatology and Venereology : JEADV vol. 28,12 (2014): 1761-7. doi:10.1111/jdv.12408

[3] U.S. Food and Drug Administration. “Drug Trials Snapshots: LETYBO.” U.S. Food and Drug Administration, 29 Feb. 2024, www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo.

[4] U.S. Food and Drug Administration. LETYBO® (LetibotulinumtoxinA-wlbg) Injection: Prescribing Information. Revised Feb. 2024, U.S. Food and Drug Administration, www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf.

[5] Gold, Michael et al. “Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females 35 to 50 Years of Age: Post Hoc Analyses of the Phase 3 Clinical Study Data.” Aesthetic surgery journal. Open forum vol. 6 ojae010. 23 Feb. 2024, doi:10.1093/asjof/ojae010

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.